Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Rhea-AI Summary

Nuvectis Pharma (Nasdaq: NVCT) priced an underwritten public offering of 5,000,000 common shares at $20.00 per share, targeting $100 million in gross proceeds, plus a 30-day option for 750,000 additional shares.

Proceeds will fund NXP100, NXP200, NXP900, hiring, capital spending and general corporate purposes.

Positive

• Public offering targets $100 million in gross proceeds at $20.00 per share
• 30-day underwriter option for up to 750,000 additional shares
• Proceeds earmarked to advance NXP100, NXP200, and NXP900 programs

Negative

• Issuance of 5,000,000 new shares increases outstanding share count
• Net proceeds depend on closing and underwriting discounts and commissions

News Market Reaction – NVCT

-35.54% 8.4x vol

60 alerts

-35.54% Session close to close

+13.5% Peak Tracked

-30.7% Trough Tracked

$776.40M Market Cap

8.4x Rel. Volume

In the Jun 30 session, NVCT declined 35.54%, reflecting a significant negative market reaction. Argus tracked a peak move of +13.5% during that session. Argus tracked a trough of -30.7% from its starting point during tracking. Our momentum scanner triggered 60 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 8.4x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -35.5% in the session following this news. A negative reaction despite positive pi...

Analysis

The stock dropped -35.5% in the session following this news. A negative reaction despite positive pipeline funding fits NVCT’s history of modest pressure around offerings, which average -1.01%. Dilution from $100 million in new equity and active shelf capacity may reinforce selling interest.

Key Figures

Shares offered: 5,000,000 shares Offer price: $20.00 per share Gross proceeds: $100 million +5 more

8 metrics

Shares offered 5,000,000 shares Underwritten public offering of common stock

Offer price $20.00 per share Public offering price for common stock

Gross proceeds $100 million Expected gross proceeds from base offering

Underwriters’ option 750,000 shares 30-day option for additional shares at offering price

Option period 30 days Underwriters’ option to purchase additional shares

Expected closing date July 1, 2026 Anticipated closing of the offering

Shelf file date February 13, 2026 Form S-3 shelf registration filing date

Shelf effectiveness February 20, 2026 Date Form S-3 was declared effective by SEC

Previous Offering Reports

3 past events · Latest: 2025-02-07 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
2025-02-07	Offering closing	Neutral	-7.3%	Closed prior common stock offering with $15.5M gross proceeds and full overallotment.
2025-02-05	Offering pricing	Neutral	+2.1%	Priced $13.5M common stock offering at $5.00 per share with 30-day option.
2025-02-04	Proposed offering	Neutral	+2.1%	Announced proposed underwritten offering of common stock under existing S-3 shelf.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past equity offerings have produced mixed reactions, with a slight average negative move across events.

Key Terms

underwritten public offering, shelf registration statement, form s-3, prospectus supplement, +1 more

5 terms

underwritten public offering financial

"today announced the pricing of its previously announced underwritten public offering of 5,000,000"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"being offered by Nuvectis pursuant to its shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-293459) filed with the U.S."

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"The preliminary prospectus supplement relating to and describing the terms of the offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

book runner financial

"Cantor is acting as sole book runner for the offering."

The book runner is the lead investment bank or financial firm that organizes and manages a new securities offering, lining up other underwriters, collecting investor orders, setting allocation and pricing, and keeping a record (the “book”) of demand. For investors, the book runner’s reputation and decisions affect how widely an issue is distributed, how fairly shares are priced and allocated, and therefore the short- and long-term trading liquidity and perceived market confidence in the new securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price of $20.00 per share, with expected gross proceeds to Nuvectis of $100 million. Nuvectis has also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to satisfaction of customary closing conditions.

Cantor is acting as sole book runner for the offering. H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners and Titan Partners, a division of American Capital Partners are acting as co-managers for the offering.

Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP100, NXP200, and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.

The shares of common stock described above are being offered by Nuvectis pursuant to its shelf registration statement on Form S-3 (File No. 333-293459) filed with the U.S. Securities and Exchange Commission (“SEC”) on February 13, 2026 and declared effective by the SEC on February 20, 2026. The preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to these shares of common stock may also be obtained, when available, by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59^th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes NXP100, a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.

NXP100 is a late-stage Factor B inhibitor with best-in-class potential as an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as the only once-daily oral treatment option for these diseases requiring life-long treatment.

NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway.

NXP200 is an oral, brain penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “could”, “estimate”, “expect”, “intend”, “seek”, “may”, “might”, “plan”, “potential”, “predict”, “project”, “target”, “aim”, “should”, “will”, “would”, or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the timing for completion of the public offering, and the use of proceeds and anticipated total gross proceeds from the public offering. Forward looking statements are based on Nuvectis’ current expectations and interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and efficacy data generated to date for its pipeline products NXP100, NXP200, and NXP900, and estimates and projections regarding Nuvectis’ financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described more fully in the section titled “Risk Factors” in Nuvectis’ first quarter 2026 Form 10-Q and Nuvectis’ other public filings with the U.S. Securities and Exchange Commission (“SEC”). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Nuvectis’ expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Other than statements of historical fact, all statements are considered forward-looking statements and are based on Nuvectis’ interpretations of past events as well as current expectations, estimates, and projections.

Company Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
Tel: 201-614-3151
rbentsur@nuvectis.com

Media Relations Contact

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

FAQ

What did Nuvectis Pharma (NVCT) announce about its June 2026 stock offering?

Nuvectis Pharma announced pricing of an underwritten public offering of 5,000,000 common shares at $20.00 per share, targeting $100 million in gross proceeds. According to Nuvectis, the deal includes a 30-day option for 750,000 additional shares.

How many shares is Nuvectis Pharma (NVCT) offering and at what price?

Nuvectis Pharma is offering 5,000,000 shares of common stock at $20.00 per share. According to Nuvectis, underwriters also have a 30-day option to buy up to 750,000 more shares at the public offering price, less underwriting discounts and commissions.

When is the Nuvectis Pharma (NVCT) $100 million offering expected to close?

The Nuvectis Pharma public offering is expected to close on or about July 1, 2026. According to Nuvectis, completion is subject to satisfaction of customary closing conditions typical for underwritten equity offerings.

How will Nuvectis Pharma (NVCT) use the proceeds from its June 2026 stock sale?

Nuvectis plans to use net proceeds to advance NXP100, NXP200, NXP900 and any future candidates. According to Nuvectis, funds will also support hiring, capital expenditures, public company costs and general corporate purposes.

Which investment banks are managing the Nuvectis Pharma (NVCT) public offering?

Cantor is acting as sole book runner for the Nuvectis Pharma offering. According to Nuvectis, H.C. Wainwright, Laidlaw, Lucid Capital Markets, Maxim Group, Roth Capital Partners and Titan Partners are serving as co-managers.

Under what SEC registration is the Nuvectis Pharma (NVCT) offering being conducted?

The offering is being conducted under a shelf registration statement on Form S-3, File No. 333-293459. According to Nuvectis, it was filed on February 13, 2026 and declared effective by the SEC on February 20, 2026.

Where can investors find the Nuvectis Pharma (NVCT) prospectus for the June 2026 offering?

Investors can access the preliminary prospectus supplement on the SEC website at www.sec.gov. According to Nuvectis, electronic copies of the final prospectus supplement will also be available from Cantor Fitzgerald’s Capital Markets group when issued.